NEW YORK (GenomeWeb News) – Single Cell Technology and AB Biosciences today announced a collaboration aimed at identifying therapeutic antibodies.

SCT will use its technology called Antibody Biologix to massively screen plasma cells and measure the kinetics of secreted antibodies. It also will use next-generation sequencing to sequence the cognate light and heavy chain mRNA.

ABB will select antibody targets, engineer protein antigens, and develop tools for characterizing antibodies identified by SCT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.